TLS data
 

Biomedical Research Funding

 
 

National Institutes of Health (NIH)

By supporting basic research, the NIH provides a critical foundation of knowledge and technologies that drive private biomedical investment and innovation across the country, and especially in California. In FY 2017, California received $3.7 billion from NIH, which has funded over 7,500 grants. Among those, Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants have allowed small businesses and start-up companies to bring innovative ideas to commercialization. However, NIH funding has been flat for the past decade and has not kept pace with inflation, which has resulted in the NIH losing nearly 25 percent of its purchasing power. Decreased investments in innovation could affect existing research, erode the U.S. global leadership in medical innovation, and lead some scientists to pursue their research in other countries.

Congress allocated $32 billion to the NIH in FY2016 and $34 billion in FY2017, increases highly welcomed by Biocom. In December 2016, Congress passed the 21st Century Cures Act, which aims at bringing new treatments and cures to patients faster, a top priority for Biocom. The bill adds funding for the NIH, with dedicated funding for major executive initiatives, including the Precision Medicine Initiative, BRAIN Initiative, and Cancer Moonshot. But Congress must continue to invest in medical innovation to enable the development of breakthrough treatments and cures. Biocom is urging the House and the Senate to increase funding for the NIH in FY2018 and FY2019.

Biodefense

Biocom continues to advocate for biodefense and pandemic research funding. Recent outbreaks, such as Ebola and Zika, have revived a nationwide debate over U.S. preparedness for emerging infectious diseases and emphasized the need for robust public-private partnerships. Biocom supports additional funding for the Project BioShield Special Reserve Fund (SRF), which incentivizes companies to develop medical countermeasures (MCMs), and the Biomedical Advanced Research and Development Authority (BARDA), which develops vaccines and treatments for chemical, biological, radiological, and nuclear (CBRN) threats, through partnerships with industry. In particular, Biocom is urging Congress to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA), set to expire on September 30, 2018, which authorizing funding for BARDA and SRF programs.

Biocom Policy Statements

  • Pandemic and All Hazards Preparedness Act (PAHPA) One-pager - Download
  • Biocom Comment Letter – NIH Strategic Plan for Data Science - Download
  • Biocom FYI2019 NIH Appropriation Request – House - Download
  • Biocom FYI2019 NIH Appropriation Request – Senate - Download
  • Biocom NIH One-Pager - Download
  • Biocom California NIH Funding Infographic - Download
  • Biocom Bay Area NIH Funding Infographic - Download
  • Biocom Los Angeles County NIH Funding Infographic - Download
  • Biocom San Diego County NIH Funding Infographic - Download
  • Biocom Statement in Response to the Administration’s Proposed Cuts to Medical Research - Download
  • Biocom 21st Century Cures Press Release - Download
 
 

Public Policy Newsletter

Members: Sign up to receive updates regarding the most important recent policy news.